| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: PHARMAID. Summary written from the filing by ALFA Finder's alert engine.
Pharmaids Pharmaceuticals Ltd: key numbers
- Share price
- ₹27.52
- Market cap
- ₹97.06 Cr
- Revenue (annual)
- ₹27.88 Cr
- Net profit (annual)
- ₹-11.72 Cr
- P/E (TTM)
- -21.3×Sector 46.1×
- Promoter holding
- 32.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pharmaids Pharmaceuticals Ltd
All →Pharmaids Pharmaceuticals Other Announcement
Pharmaids Pharmaceuticals Limited filed its quarterly Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent confirming the dematerialization of shares.
Pharmaids Pharmaceuticals Legal & Regulatory
Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.
- Value
- ₹2.63 Cr
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
Pharmaids Pharmaceuticals Promoter Buying (Off-Market)
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
- Promoter stake change
- +0.04%
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals Limited has issued the notice for its 37th Annual General Meeting, scheduled for September 11, 2026, along with the Annual Report for 2025-26.
Pharmaids Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.9 Cr, Down 64.2% YoY
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.1 Cr (-38.8% YoY) and net profit of ₹1.9 Cr (-64.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.9 Cr · -64.2% YoY
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.